Cargando…
Aducanumab-Related Amyloid-Related Imaging Abnormalities: Paean or Lament?
When the FDA granted accelerated approval of Biogen's Alzheimer disease drug, aducanumab (marketed as Aduhelm), it deviated from its mission of guaranteeing drug safety and efficacy because the approval was based exclusively on a perceived dose-dependent reduction in brain amyloid deposits and...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9169751/ https://www.ncbi.nlm.nih.gov/pubmed/35452007 http://dx.doi.org/10.1097/RLU.0000000000004250 |